Pfizer raises 2026 forecasts on strong demand for Eliquis, cancer drugs

What happened

Pfizer raised its annual profit and revenue forecasts, expecting 2026 sales of $62 billion to $64.0 billion and adjusted earnings per share of $2.95 to $3.05. It also named Cecile Guegan as chief financial officer, effective November 1.

Confirmed

Global impact / market context

Higher forecasts suggest Pfizer sells more cancer drugs and Eliquis than expected, which means more revenue and profit per sale. That cash can fund licensing deals and acquisitions needed as patent expirations threaten sales of older top drugs after 2028.

Analyst inference

Analysts expected 2026 earnings per share of $2.96 and revenue of $62.17 billion, so the new sales range lands above that midpoint. Total revenue of $16.58 billion beat estimates of $15.87 billion, showing current demand is strong even as looming patent losses shape Pfizer's deal strategy.

Analyst inference

What to watch

1. Cecile Guegan becomes chief financial officer on November 1, succeeding Dave Denton, who left in August for a similar role at Nike. Confirmed
2. Watch whether Eliquis and cancer drug demand keeps sales inside Pfizer's $62 billion to $64.0 billion range, because falling short would weaken the case for higher profit. Analyst inference
3. Watch for licensing deals or acquisitions that Pfizer says will replace revenue lost when patents expire after 2028, a risk it names as a reason for dealmaking. Proposed

Evidence

• Original source link unavailable